Autopsy report · NCT01528930
Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease
Cause of deathSafety
“Although this study was approved at the Institutional Review Board, Korea Food \& Drug Administration (KFDA) did not approve this study due to safety concern.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Samsung Medical Center
- Sponsor type
- University, hospital or other
- Conditions
- Pulmonary Non-tuberculous Mycobacterial Lung Disease
- Interventions
- Amikacin
- Participants
- 0
- Sites
- 1
- Countries
- South Korea
Trials that died the same way
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
“This study was terminated due to limited efficacy and not due to safety reasons” - Iontophoresis in Psoriasis
“FDA did not provide approval of the use of the drug for the study” - Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
“This study was terminated for reasons not related to efficacy or safety” - A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
“The study was terminated by Sponsor and the decision was not due to any safety or efficacy reasons.” - A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
“The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.